TrialBlood advances2024

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.

Mats Jerkeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.